{
    "clinical_study": {
        "@rank": "104161", 
        "acronym": "REVERT", 
        "arm_group": {
            "arm_group_label": "Peri or post-menopausal women.", 
            "description": "Women with peri or post-menopausal vasomotor symptoms between 30 and 60 years of age."
        }, 
        "brief_summary": {
            "textblock": "Bioidentical Hormone Replacement Therapy (BHRT) to assess a change in the number of various\n      menopausal symptoms such as hot flashes and night sweats in surgically or naturally induced\n      peri or post-menopausal women."
        }, 
        "brief_title": "Relieving Vasomotor Symptoms Effectively With Bioidentical Hormone Replacement Therapy: The REVERT Study", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Menopause", 
        "detailed_description": {
            "textblock": "Participants will be receiving a customized bioidentical hormone regimen which may include a\n      combination of estrogens, progesterone, and testosterone."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Participants must be women who are in surgically or naturally induced menopause or\n             perimenopause, as determined by their physician.\n\n          -  Participants must be starting a new regimen of bioidentical hormone replacement\n             therapy.\n\n          -  Participants must be expected to receive therapy for at least 12 weeks.\n\n          -  Participants must be between 30 and 65 years of age.\n\n          -  Participants must be able to provide sound written informed consent or have an\n             acceptable surrogate capable of giving consent on the subject's behalf.\n\n        Exclusion Criteria:\n\n          -  Participants must not have prior hypersensitivity or adverse events to any of the\n             components in the customized prescription.\n\n          -  Participants must not be pregnant or breastfeeding women.\n\n          -  Participants must not be managed outside the Medimix Specialty Pharmacy system with\n             regard to their bioidentical hormone replacement therapy.\n\n          -  Participants must not be using another bioidentical hormone at the time of\n             enrollment."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "30 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Peri-menopausal or post-menopausal women between the age of 30 and 65 years of age."
            }
        }, 
        "enrollment": {
            "#text": "69", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "May 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01862861", 
            "org_study_id": "Medimix Pharm-02"
        }, 
        "intervention_browse": {
            "mesh_term": "Hormones"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Bioidentical Hormone Replacement Therapy", 
        "lastchanged_date": "May 22, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Jacksonville", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "32216"
                }, 
                "name": "The Medimix Specialty Pharmacy, LLC"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "Relieving Vasomotor Symptoms Effectively With Bioidentical Hormone Replacement Therapy: The REVERT Study", 
        "overall_official": {
            "affiliation": "The Medimix Specialty Pharmacy, LLC", 
            "last_name": "Benjamin J Epstein, PharmD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The reduction of severity of vasomotor symptoms will be evaluated by utilizing the Menopause Rating Scale (MRS) from baseline to the end of study at 12 weeks.", 
            "measure": "To evaluate the efficacy of bioidentical hormone replacement therapy in decreasing the severity of vasomotor symptoms.", 
            "safety_issue": "No", 
            "time_frame": "12 Week Study"
        }, 
        "reference": [
            {
                "PMID": "19179815", 
                "citation": "Holtorf K. The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy? Postgrad Med. 2009 Jan;121(1):73-85. doi: 10.3810/pgm.2009.01.1949. Review."
            }, 
            {
                "PMID": "16735636", 
                "citation": "Gold EB, Colvin A, Avis N, Bromberger J, Greendale GA, Powell L, Sternfeld B, Matthews K. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation. Am J Public Health. 2006 Jul;96(7):1226-35. Epub 2006 May 30."
            }, 
            {
                "PMID": "15495039", 
                "citation": "Maclennan AH, Broadbent JL, Lester S, Moore V. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD002978. Review."
            }, 
            {
                "PMID": "15555079", 
                "citation": "Heinemann LA, DoMinh T, Strelow F, Gerbsch S, Schnitker J, Schneider HP. The Menopause Rating Scale (MRS) as outcome measure for hormone treatment? A validation study. Health Qual Life Outcomes. 2004 Nov 22;2:67."
            }, 
            {
                "PMID": "9699235", 
                "citation": "Julious SA, Campbell MJ. Sample size calculations for paired or matched ordinal data. Stat Med. 1998 Jul 30;17(14):1635-42."
            }, 
            {
                "PMID": "10379691", 
                "citation": "Julious SA, Campbell MJ, Altman DG. Estimating sample sizes for continuous, binary, and ordinal outcomes in paired comparisons: practical hints. J Biopharm Stat. 1999 May;9(2):241-51."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01862861"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The quality of life (HrQol) will be evaluated by utilizing the Women's Health Questionnaire (WHQ)at baseline and at end of study at 12 weeks.", 
            "measure": "To evaluate health-related quality of life (HrQol)", 
            "safety_issue": "No", 
            "time_frame": "12 Weeks"
        }, 
        "source": "Medimix Specialty Pharmacy, LLC", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medimix Specialty Pharmacy, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2013"
    }
}